Screener
BioCryst Pharmaceuticals BCRX Business Segments — Stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other non-program specific and indirect costs | 7,044 | 6,743 | 14,463 | 13,289 |
| Sales and marketing (excluding stock-based compensation) | 33,947 | 45,589 | 76,900 | 93,259 |
| General and administrative (excluding stock-based compensation) | 20,810 | 29,817 | 63,203 | 51,776 |
| Stock-based compensation | 14,692 | 21,304 | 30,719 | 42,672 |
| Interest income | (2,434) | (2,516) | (4,690) | (5,540) |
| Interest expense | 21,712 | 21,582 | 41,491 | 45,076 |
| Foreign currency (gains) losses | (27) | 63 | 198 | 62 |
| Loss on extinguishment of debt | — | 4,171 | — | 4,171 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's business segments — stock-based compensation expense?
- BioCryst Pharmaceuticals (BCRX) reported business segments — stock-based compensation expense of $14.69M in Q2 2026.
- How has BioCryst Pharmaceuticals's business segments — stock-based compensation expense changed year-over-year?
- BioCryst Pharmaceuticals's business segments — stock-based compensation expense decreased by 31.0% year-over-year, from $21.3M to $14.69M.
- What does business segments — stock-based compensation expense mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and executives within the segment. This metric is essential for understanding the total cost of human capital and the potential dilution impact on shareholders.
Ask your AI about BioCryst Pharmaceuticals's business segments — stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude